Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.57 |
| ▸ | CNR1 | P21554 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14410946 | 0.89 | CNR2 (0.54) | CNR2CNR1CHRM1CHRM2CHRM4 | |
| SCHEMBL5450970 | 0.88 | CNR2 (0.53) | CNR2CNR1CHRM1CHRM2CHRM4 | |
| SCHEMBL5463133 | 0.86 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL5450940 | 0.86 | CNR2 (0.52) | CNR2CNR1DRD2DRD4 | |
| SCHEMBL14463728 | 0.84 | CNR2 (0.51) | CNR2CNR1DRD2 | |
| SCHEMBL5443941 | 0.84 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL14411115 | 0.84 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL5451529 | 0.83 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL5453439 | 0.83 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL5446832 | 0.83 | CNR2 (0.49) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885CNR1 65/4885CHRM1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.